Medication info

Cheonbok Fluorouracil 250mg (Fluorouracil)

Prescription medicationInjectionsIntravenous injectionExpired
Ingredient · strength
Fluorouracil›50mg / 1mL
Manufacturer / importer
Daegu-Gyeongbuk Medical Innovation Foundation
Appearance
A clear, colorless liquid in a colorless, transparent vial injection
Packaging
5 milliliters/vial - 5 milliliters/vial
Approval status
Expired

MFDS item code 201904804 · Notified 2019.07.18

This product's status changed to Expired on 2024.07.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Relief of symptoms of carcinomas (colon cancer, rectal cancer, etc.) and cancers for which it is used in combination (esophageal cancer, lung cancer, etc.)
Who receives it
Adults
Adult administration
1. Intravenous injection (systemic administration): As monotherapy, the usual adult dose is 5~15 mg of fluorouracil per kg of body weight daily (not more than 1g per infusion), dissolved in 300~500 mL of 5% dextrose injection, administered by intravenous drip daily for 5 days. Thereafter, administer 5~7.5 mg per kg of body weight by intravenous drip every other day. Discontinue administration if adverse reactions occur. 2. Intra-arterial injection: As monotherapy, the usual adult dose is 5~7.5 mg of this medicine per kg of body weight daily, dissolved in 20~100 mL of 5% dextrose injection and continuously infused using an infusion pump for 10~20 days. 3. Combination with radiotherapy: The usual adult dose is 5~10 mg of this medicine per kg of body weight daily, administered in combination with radiotherapy in the same manner as for monotherapy. 4. Combination with other antineoplastic agents: The usual adult dose is 5~10 mg of this medicine per kg of body weight daily, administered in combination with other antineoplastic agents in the same manner as for monotherapy or intermittently 1~2 times a week.

Ingredients

Manufacturer
Daegu-Gyeongbuk Medical Innovation Foundation

Efficacy & effects

Relief of symptoms of carcinomas (colon cancer, rectal cancer, etc.) and cancers for which it is used in combination (esophageal cancer, lung cancer, etc.)

  • Subjective symptoms
  • Objective symptoms
View approved original text

This medication is used to relieve subjective and objective symptoms occurring in various cancers such as colon cancer, rectal cancer, breast cancer, stomach cancer, liver cancer, pancreatic cancer, ovarian cancer, and uterine cancer. It is also used in conjunction with other antitumor agents or radiotherapy to enhance therapeutic effects for specific cancers such as esophageal cancer, lung cancer, sarcoma, and oral cancer. It plays a significant role in effectively managing the symptoms of various cancer types and assisting in treatment.

How it is given

Adult administration

1. Intravenous injection (systemic administration): As monotherapy, the usual adult dose is 5~15 mg of fluorouracil per kg of body weight daily (not more than 1g per infusion), dissolved in 300~500 mL of 5% dextrose injection, administered by intravenous drip daily for 5 days. Thereafter, administer 5~7.5 mg per kg of body weight by intravenous drip every other day. Discontinue administration if adverse reactions occur. 2. Intra-arterial injection: As monotherapy, the usual adult dose is 5~7.5 mg of this medicine per kg of body weight daily, dissolved in 20~100 mL of 5% dextrose injection and continuously infused using an infusion pump for 10~20 days. 3. Combination with radiotherapy: The usual adult dose is 5~10 mg of this medicine per kg of body weight daily, administered in combination with radiotherapy in the same manner as for monotherapy. 4. Combination with other antineoplastic agents: The usual adult dose is 5~10 mg of this medicine per kg of body weight daily, administered in combination with other antineoplastic agents in the same manner as for monotherapy or intermittently 1~2 times a week.

Precautions

This drug may cause serious blood disorders when used in conjunction with specific antiviral agents, so co-administration should be strictly avoided. During administration, it should be under strict supervision by a physician, and it should only be administered in a medical facility equipped for emergencies with experienced doctors. Regular liver function tests should be conducted, and attention should be paid to early symptoms of liver impairment, as liver function may be affected. Coadministration with certain combination drugs may also lead to serious blood disorders and should be avoided. Some patients, especially women who are pregnant or may become pregnant, nursing mothers, patients with severe bone marrow suppression, and those with specific enzyme deficiencies should not use this drug. Patients with poor nutritional status, liver, kidney, or heart diseases, elderly patients, and children should use this drug carefully, with special attention to adverse reactions. This drug can cause various adverse reactions affecting multiple systems such as the central nervous system, digestive system, circulatory system, blood, liver, kidneys, and skin; any symptoms should be carefully observed, and use should be discontinued immediately if problems arise. Regular blood tests and liver and kidney function tests should be performed during treatment to promptly detect and take appropriate actions for any adverse reactions. Particular attention is needed for drugs that interact with this medication, and consultations with a doctor or pharmacist about other medications being used are essential. It is preferable for women who are pregnant or nursing not to use this drug, and careful administration is also needed for children and the elderly. In case of overdose, symptoms like dizziness and movement disorders may occur, requiring immediate treatment. This drug can cause damage to the skin or blood vessels upon injection, so the injection site should be monitored closely, and administration should be discontinued if abnormalities are observed. This drug should not be mixed physically with certain chemotherapeutic agents, and caution is needed during preparation.

Side effects

Extrapyramidal symptoms, facial paralysis, speech disorders, ataxia, eye tremor, altered consciousness, seizures, directional sense disturbance, paresthesia of the limbs, hallucinations, memory impairment, decreased spontaneity, urinary incontinence, leukoencephalopathy, Parkinsonian symptoms, fatigue, dizziness, reversible posterior leukoencephalopathy syndrome, loss of appetite, nausea, vomiting, diarrhea, altered taste, polydipsia, abdominal distension, abdominal pain, bleeding, constipation, angular cheilitis, glossitis, severe enteritis, gastrointestinal ulcer, severe stomatitis, acute pancreatitis, intestinal emphysema, lactic acidosis, tumor lysis syndrome, congestive heart failure, myocardial infarction, stable angina, pain, electrocardiogram abnormalities, chest pain, chest discomfort, stress cardiomyopathy, pancytopenia, leukopenia, neutropenia, anemia, thrombocytopenia, hyperammonemia, hepatitis, liver dysfunction, jaundice, liver failure, acute renal failure, renal dysfunction, proteinuria, olfactory dysfunction, hyposmia, shock, anaphylactic symptoms, rash, respiratory distress, hypotension, interstitial pneumonia, fulminant hepatitis, cirrhosis, ventricular tachycardia, nephrotic syndrome, skin and mucous membrane syndrome, toxic epidermal necrolysis, hemolytic anemia, biliary tract disorder, hand-foot syndrome, hyperpigmentation, hair loss, edema, ulceration, blisters, itching, flushing, abnormal nails, photodermatitis, skin erythema lupus, conjunctivitis, lacrimation, fever, headache, diabetes, hypocalcemia, impaired glucose tolerance, pneumonia, sepsis, speech impairment, myocarditis, cardiogenic shock, sudden cardiac arrest, electrocardiogram changes, cardiotoxicity, white matter encephalopathy, encephalopathy, confusion, disorientation, coma, ataxia, hyperammonemic encephalopathy, increased serum ammonia levels, elevated serum amylase, thrombocytopenia, blood disorders, increased serum fluorouracil concentration, abnormal blood findings, blood disorders, decreased platelet count, decreased white blood cell count, platelet count less than 100,000, white blood cell count less than 3,500, stomatitis, mucosal inflammation, neutropenia, neurotoxicity, dizziness, nystagmus, limb ataxia, Parkinsonian symptoms, arterial wall alteration, thrombogenesis, skin necrosis, vascular pain, phlebitis, acute leukemia, myelodysplastic syndrome

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air, away from direct sunlight, and at room temperature between 1 to 30 degrees Celsius. Proper storage will maintain the drug's effectiveness and prevent degradation.

Appearance and packaging

Appearance

A clear, colorless liquid in a colorless, transparent vial injection

Package unit

5 milliliters/vial - 5 milliliters/vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.